Salute e Benessere

Sandoz enters global collaboration license agreement with Henlius to…

MEDIA RELEASE Agreement offers rights to commercialize proposed biosimilar of Yervoy®* for treatment of variety of cancer types, targeting net reference medicine sales of USD 2.5 billion[1]Henlius to develop and manufacture biosimilar, with Sandoz to register and commercialize after expiry of relevant patents across global marketsCombination therapy of ipilimumab and nivolumab used in 95% of eligible patients[2]; ipilimumab highly complementary to proposed Sandoz nivolumab biosimilar...
Nasdaq GlobeNewswire
29/04/2025

Collagen & Gelatin Market worth US$1,671.3 million in 2030 5.8% CAGR |…

Browse in-depth TOC on "Collagen & Gelatin Market" Browse in-depth TOC on "Collagen & Gelatin Market" 228 - Tables 44 - Figures 240 - Pages By Based on segment,the collagen & gelatin market is divided into bovine, porcine, and others. The large share of the bovine segment can be attributed to the growing adoption of bovine-derived collagen and gelatin in regenerative medicine. Additionally, the increased usage of biomaterials is primarily due to the…
PR Newswire
29/04/2025

Active Pharmaceutical Ingredients (API) Market to Amass $359.45 Billion by 2030…

The demand for API has risen on the back of the prevalence of chronic diseases, such as cardiovascular diseases (CVD), diabetes and cancer. To illustrate, according to a study published in the U.S. Pharmacist in 2020 and later reported by the CDC in May 2024, around 47% of adults have at least one of the three risk factors (high blood pressure, high LDL cholesterol and smoking) for cardiovascular disease. An upsurge in CVD has aggravated public health burdens, thereby boosting R&D in APIs…
PR Newswire
29/04/2025

Acousia Therapeutics Reaches 50% Patient Enrollment Milestone in Phase 2 PROHEAR…

The PROHEAR Study is a placebo-controlled, randomized, double-blind, split-body trial in which participants receive ACOU085, a Kv7.4 channel activator, in one ear and a placebo in the contralateral ear. The study is currently being conducted at 13 leading German ENT university clinics and is still actively recruiting. ThePROHEAR Studyis aplacebo-controlled, randomized, double-blind, split-body trialin which participants receiveACOU085, a Kv7.4 channel activator, in one ear and a...
PR Newswire
29/04/2025

Metabolon Launches Microbiome Research Solution Combining New Microbiome Panel…

While metagenomics identifies microbial species and their genetic potential, it does not reveal their functional contributions – specifically, the metabolic activities and bioactive compounds that microbes produce that may impact the host. Metabolomics, which measures the collection of small molecules in a sample, addresses this need by offering a phenotypic snapshot of microbiome activity. Metabolites are critical mediators linking microbial functions to host physiology, immune responses, and…
PR Newswire
29/04/2025

Gifthealth Appoints Chip Parkinson as Chief Executive Officer to Accelerate…

"Gifthealth is uniquely positioned to simplify pharmacy access through innovation and investment in patient-focused services," said Parkinson. "I'm honored to join this mission-driven team and look forward to building on the company's strong foundation to expand our impact and serve more people nationwide." "Gifthealth is uniquely positioned to simplify pharmacy access through innovation and investment in patient-focused services," said Parkinson. "I'm honored…
PR Newswire
29/04/2025

Zelluna ASA – Annual General Meeting held on April 29, 2025

Oslo, April 29, 2025:Zelluna ASA held its annual general meeting today April 29, 2025. All the matters on the agenda were approved. The minutes from the meeting are enclosed and available at the company's website.For further information, please seewww.zelluna.comor contact: Anders Tuv, Chairman of the Board of Directors of Zelluna ASAEmail: [email protected]: +47 982 06 826 Namir Hassan, CEO, Zelluna ASAEmail: [email protected]: +44 7720 687608 Hans...
Nasdaq GlobeNewswire
29/04/2025

Breaking new ground in mental health research: Oxford University, Boehringer…

Ingelheim, Germany, Oxford and Belfast, UK, April 29, 2025 – Boehringer Ingelheim, the University of Oxford , and Cumulus Neuroscience are joining forces to provide insights into the day-to-day experiences of people living with psychiatric disorders, and how these experiences relate to their brain activity. The first-of-its-kind study will use novel technology to quantify brain activity, mood , and behavior at home in peoplewho have been...
Nasdaq GlobeNewswire
29/04/2025

Continuity Biosciences Invests in PinPrint, Inc., Expanding into Aesthetic and…

PinPrint's lead innovation is a next-generation microneedle patch designed to deliver vaccines and active agents intradermally, replacing the need for traditional injections. "By integrating high-resolution 3D printing with advanced drug delivery, we're redefining the patient experience across therapeutic and cosmetic categories—offering a new standard for precision, personalization, and comfort," said Dr. DeSimone. PinPrint's lead innovation is a next-generation microneedle patch…
PR Newswire
29/04/2025

Lutris Pharma Announces the Appointment of Seasoned Life Science Executive…

"Sumant brings a wealth of experience in the biopharmaceutical industry, with a track record of leadership across innovative organizations spanning oncology, immunology, and advanced therapeutics. His appointment comes at a pivotal time for Lutris Pharma as we continue the clinical development of lead compound, LUT014 gel. On behalf of the Board of Directors, I am pleased to welcome Sumant and look forward to leveraging his deep insights and expertise," stated Ran Nussbaum, a member of…
PR Newswire
29/04/2025

Press Release: When every second counts: Sanofi, McLaren Racing and United…

When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours raceParis, April 29, 2025 .Sanofi is proud to unveil an exciting new chapter in its mission to fight meningitis, as it expands its partnership with McLaren Racing for a powerful activation alongside United Autosports, the official racing partner of McLaren Automotive. This unique collaboration will see the Meningitis Flag — a powerful symbol...
Nasdaq GlobeNewswire
29/04/2025

MolecuLight and DocNow Announce Integration for Seamless Data and Image Transfer…

Key benefits of the now available MolecuLightDX and DocNow EHR integration include: Key benefits of the now available MolecuLight DXand DocNow EHR integration include: "The integration with DocNow represents a significant advancement in our commitment to providing clinicians with immediate, actionable insights at the point of care," states Anil Amlani, CEO of MolecuLight Inc. "The MolecuLightDX, a rigorously validated FDA cleared Class II device, offers critical information about…
PR Newswire
29/04/2025

Vistin Pharma ASA: Notice of Annual General Meeting 22 May 2025

Vistin Pharma ASA (OSE: VISTN), please find attached the call for the Annual General Meeting in Vistin Pharma, to be held on 22 May 2025 at 13:00 CEST.A physical Annual General Meeting will not be held. Instead, shareholders should authorize the Chairman of the Board. It is possible to give proxy with and without voting instructions. By using a proxy with voting instructions, the shareholders will vote on the specific issues without personal attendance. For further information on the use...
Nasdaq GlobeNewswire
29/04/2025

GammaPod revolutionizes breast cancer treatment: Italy introduces high-dose…

GammaPod represents a true revolution in the treatment of breast cancer: it allows the safe and precise administration of high doses of radiation to the tumor because, unlike conventional radiotherapy equipment, designed to treat tumors in all areas of the body, GammaPod was invented and designed to treat only breast cancer. For this reason, it is able to concentrate the entire dose on the tumor alone, drastically reducing exposure and damage to surrounding healthy tissue, thus minimizing side…
PR Newswire
29/04/2025

Novo Nordisk Foundation expands Challenge Programme outside of Denmark for the…

This year, the budget for each grant has been increased by 25% to up to DKK 75 million (€10 million) over six years, bringing the overall budget to DKK 600 million (€80 million). This year, the budget for each grant has been increased by 25% to up toDKK 75 million(€10 million) over six years, bringing the overall budget toDKK 600 million(€80 million). Mads Krogsgaard Thomsen, CEO, Novo Nordisk Foundation, says: "The Novo Nordisk Foundation is dedicated to help solving some of the...
PR Newswire
29/04/2025

One of the world's most prestigious cancer centers adopts Sectra for integrated…

"The integrated diagnostics approach, where medical specialties collaborate around patient cases to make faster and more accurate diagnoses and treatment decisions, is especially beneficial in cancer care. We are excited to support and follow this cancer center on their journey towards cloud and towards integrated diagnostics," says Marie Ekström Trägårdh, Executive Vice President of Sectra AB and President of Sectra Imaging IT Solutions. "The integrated diagnostics approach…
PR Newswire
29/04/2025

Sobi publishes Q1 2025 report: Portfolio continues to deliver

Outlook 2025 - Unchanged Outlook 2025 - Unchanged * The strategic portfolio includes Sobi's medicines Altuvoct, Aspaveli/Empaveli, Doptelet, Gamifant, Vonjo and Zynlonta, and royalty on Sanofi's sales of Altuviiio and Beyfortus. Investors, analysts, and the media are invited to a conference call on the same day at15:30 CET,14:30 GMT, and09:30 EST. The call will include a presentation of the results and a Q&A session. The presentation can be followed livehere or...
PR Newswire
29/04/2025

Statement re Grant of Options and Warrants

DXS INTERNATIONAL PLC(AQSE: DXSP)Granting of Share Options and Warrants The Board of DXS International plc (the “Company” or “DXSP), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems, announces that it yesterday granted share options to a number of directors, employees, and consultants. Most of these options grants are under an Enterprise Management Incentive (“EMI”) scheme and the remainder under an unapproved share...
Nasdaq GlobeNewswire
29/04/2025

CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI®…

EU approval is based on the complete data set from the phase-III PROTECT study EU approval is based on the complete data set from the phase-III PROTECT study ST. GALLEN,SwitzerlandandSAN DIEGO , April 29, 2025 /PRNewswire/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) are pleased to announce that the European Commission has approved the conversion of the conditional marketing approval (CMA) into a standard marketing authorization (MA) for FILSPARI for the...
PR Newswire
29/04/2025

The Board of Directors of Financière de Tubize appoints Bruno Holthof as new…

The Board of Directors of Financière de Tubize appoints Bruno Holthof as new ChairAs Gaëtan Hannecart did not seek renewal of his director's mandate at the general shareholders meeting held on April 25, 2025, the Board of Directors of Financière de Tubize, during its meeting held on the same day, elected Bruno Holthof, currently Independent Director, as chair of the company's board of directors with effect as of April 25, 2025.Gaëtan Hannecart commented: “I am very proud of the progress we...
Nasdaq GlobeNewswire
29/04/2025

Santhera Full Year Results for the Year Ended 31 December 2024

Transformational year following the successful launch of AGAMREE®Pratteln, Switzerland, April 29, 2025–Santhera Pharmaceuticals (SIX: SANN) today announces its full year results for the year ended 31 December 2024.Dario Eklund, CEO of Santhera said:“The year 2024 marked a transformational period for Santhera, with the successful launch of AGAMREE® for the treatment of Duchenne muscular dystrophy in Germany and Austria, and in the U.S. by our licensing partner Catalyst...
Nasdaq GlobeNewswire
29/04/2025

Vivoryon Therapeutics N.V. Reports Full Year 2024 Financial Results and Provides…

Vivoryon Therapeutics N.V. Reports Full Year 2024 Financial Results and Provides Business Update Successful strategic shift towards a focus on inflammatory and fibrotic diseases, in particular on kidney diseaseVaroglutamstat Phase 2 program shows highly consistent, statistically significant and clinically meaningful improvement of kidney function (eGFR) versus placebo in two independent randomized double-blind placebo-controlled studiesStatistical evidence from meta-analysis of...
Nasdaq GlobeNewswire
29/04/2025

Novartis continues strong momentum with double-digit sales growth, robust margin…

Ad hoc announcement pursuant to Art. 53 LR Net sales grew +15% (cc 1, +12% USD) with core operating income 1up +27% (cc, +23% USD) Sales growth driven by continued strong performance fromEntresto(+22% cc),Kisqali(+56% cc),Kesimpta(+43% cc),Cosentyx(+18% cc),Leqvio(+72% cc) andScemblix(+76% cc) Core operating income margin 1reached 42.1%, +400 basis points (cc), mainly driven by higher net sales Operating income grew +44% (cc, +38% USD); net...
Nasdaq GlobeNewswire
29/04/2025

Santhera Publishes Agenda for its Annual General Meeting

Pratteln, Switzerland, April 29, 2025 – Santhera Pharmaceuticals (SIX: SANN) today published the invitation to its Annual General Meeting (AGM), which will be held on May 20, 2025, at 10:00 CEST at Haus der Wirtschaft, Hardstrasse 1, 4133 Pratteln, Switzerland. The invitation to the AGM with agenda items and explanations will be sent to registered shareholders by mail and can be viewed on Santhera's website atwww.santhera.com/investors-and-media/investor-toolbox/share-bondholder-meetings...
Nasdaq GlobeNewswire
29/04/2025
Altri  Comunicati